EP1322326A4 - Gegen das angeborene immunsystem gerichtete impfstoffe - Google Patents

Gegen das angeborene immunsystem gerichtete impfstoffe

Info

Publication number
EP1322326A4
EP1322326A4 EP01965846A EP01965846A EP1322326A4 EP 1322326 A4 EP1322326 A4 EP 1322326A4 EP 01965846 A EP01965846 A EP 01965846A EP 01965846 A EP01965846 A EP 01965846A EP 1322326 A4 EP1322326 A4 EP 1322326A4
Authority
EP
European Patent Office
Prior art keywords
boned
immune system
vaccines against
vaccinated
vaccinated vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP01965846A
Other languages
English (en)
French (fr)
Other versions
EP1322326A1 (de
Inventor
Ruslan M Medzhitov Ph D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/752,832 external-priority patent/US20020061312A1/en
Application filed by Yale University filed Critical Yale University
Publication of EP1322326A1 publication Critical patent/EP1322326A1/de
Publication of EP1322326A4 publication Critical patent/EP1322326A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6025—Nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP01965846A 2000-07-31 2001-07-31 Gegen das angeborene immunsystem gerichtete impfstoffe Ceased EP1322326A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22204200P 2000-07-31 2000-07-31
US222042P 2000-07-31
US25832900P 2000-12-28 2000-12-28
US258329P 2000-12-28
US752832 2001-01-03
US09/752,832 US20020061312A1 (en) 2000-07-31 2001-01-03 Innate immune system-directed vaccines
US28260401P 2001-04-09 2001-04-09
US282604P 2001-04-09
PCT/US2001/024228 WO2002009748A1 (en) 2000-07-31 2001-07-31 Innate immune system-directed vaccines

Publications (2)

Publication Number Publication Date
EP1322326A1 EP1322326A1 (de) 2003-07-02
EP1322326A4 true EP1322326A4 (de) 2005-08-17

Family

ID=27499260

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01965846A Ceased EP1322326A4 (de) 2000-07-31 2001-07-31 Gegen das angeborene immunsystem gerichtete impfstoffe

Country Status (5)

Country Link
EP (1) EP1322326A4 (de)
CN (1) CN1549726A (de)
AU (2) AU8640501A (de)
CA (1) CA2418036A1 (de)
WO (1) WO2002009748A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
SI1077722T1 (sl) 1998-05-22 2007-02-28 Ottawa Health Research Inst Metode in produkti za induciranje sluznicne imunosti
EP1379552B2 (de) 2001-04-20 2014-11-19 The Institute for Systems Biology Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren
US8703146B2 (en) 2001-04-20 2014-04-22 Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
DE10217254A1 (de) 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005042017A1 (en) * 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
US8420102B2 (en) 2006-03-07 2013-04-16 Vaxinnate Corporation Compositions that include hemagglutinin
EP2374474A1 (de) 2005-01-19 2011-10-12 Vaxinnate Corporation Zusammensetzungen mit Pathogen-assoziierten Molekularstrukturen und Antigene sowie ihre Verwendungen zur Stimulation einer Immunantwort
TW201402124A (zh) * 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP2650311A3 (de) 2007-11-27 2014-06-04 Ablynx N.V. Gegen heterodimere Cytokine und/oder deren Rezeptoren gerichtete Aminosäuresequenzen und Polypeptide damit
AU2009236585B2 (en) 2008-04-18 2013-03-07 Vaxinnate Corporation Deletion mutants of flagellin and methods of use
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
JP6027011B2 (ja) 2010-10-26 2016-11-16 エーシー イミューン ソシエテ アノニム 疎水性部分によって修飾されたペプチドを含むリポソームベースの構築物
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
RU2687026C2 (ru) * 2013-02-05 2019-05-06 Нитто Денко Корпорейшн Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения
MX2015014438A (es) * 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
MX2017015404A (es) * 2015-06-02 2018-05-22 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport Visualizacion de superficie de antigenos en vesiculas de membrana externa gram-negativas.
JP2018531783A (ja) * 2015-10-14 2018-11-01 ノボザイムス アクティーゼルスカブ 水濾過膜の洗浄
CA3061077A1 (en) 2016-04-26 2017-11-02 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue
CN109843327B (zh) * 2016-07-07 2022-05-13 小利兰·斯坦福大学托管委员会 抗体佐剂缀合物
EP3735265A4 (de) 2018-01-03 2021-11-10 Qu Biologics Inc. Angeborenes targeting von adoptiven zelltherapien
CN112940135B (zh) * 2019-12-11 2025-06-27 四川农业大学 融合蛋白、其氨基酸序列、编码核苷酸序列、制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006590A1 (en) * 1986-04-21 1987-11-05 Bioenterprises Pty. Ltd. Immunopotentiation
WO1996032963A1 (en) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
WO1996040290A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Immunological combination compositions and methods
WO1999039735A1 (en) * 1998-02-06 1999-08-12 Research Development Foundation Live vaccine for human immunodeficiency virus
WO1999047168A2 (en) * 1998-03-16 1999-09-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 t cell-independent antigens conjugated to lipid or lipid-containing moieties
WO1999049892A2 (fr) * 1998-03-27 1999-10-07 Pierre Fabre Medicament Utilisation de conjugues p40 actifs par voie nasale

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68926919T2 (de) * 1988-09-26 1997-01-30 Biotech Australia Pty Ltd Vakzin gegen Nematoden
DE69033600T2 (de) * 1989-03-09 2001-04-05 American Cyanamid Co., Madison Verfahren zur Isolierung von Haemopnilus influenzae Protein-E
WO1992002621A2 (en) * 1990-08-08 1992-02-20 Biomay Biotechnik Produktions- Und Handelsgesellschaft M.B.H. Allergens of alder pollen and applications thereof
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE19529302A1 (de) * 1995-08-09 1997-02-13 Siemens Ag Vorrichtung zur Kompensation von Oberschwingungsströmen einer aus mehreren Leitern bestehenden Übertragungsstrecke

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987006590A1 (en) * 1986-04-21 1987-11-05 Bioenterprises Pty. Ltd. Immunopotentiation
WO1996032963A1 (en) * 1995-04-17 1996-10-24 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
WO1996040290A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories, Inc. Immunological combination compositions and methods
WO1999039735A1 (en) * 1998-02-06 1999-08-12 Research Development Foundation Live vaccine for human immunodeficiency virus
WO1999047168A2 (en) * 1998-03-16 1999-09-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to type-2 t cell-independent antigens conjugated to lipid or lipid-containing moieties
WO1999049892A2 (fr) * 1998-03-27 1999-10-07 Pierre Fabre Medicament Utilisation de conjugues p40 actifs par voie nasale

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
BECKER R S ET AL: "CO-ADMINISTRATION OF SOLUBLE AND PARTICULATE FORMS OF CONJUGATE, OSPA, AND HA ANTIGENS SYNERGISTICALLY ENHANCE IMMUNE RESPONSES", VACCINES MODERN APPROACHES TO NEW VACCINES, NEW YORK, NY, US, January 1993 (1993-01-01), pages 347 - 351, XP000574928 *
EAVES-PYLES ET AL, THE JOURNAL OF IMMUNOLOGY, vol. 166, 15 January 2001 (2001-01-15), pages 1248 - 1260, XP002210841 *
ERDILE L F ET AL: "OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 15, no. 9, June 1997 (1997-06-01), pages 988 - 995, XP004115364, ISSN: 0264-410X *
FEARON D T ET AL: "THE INSTRUCTIVE ROLE OF INNATE IMMUNITY IN THE ACQUIRED IMMUNE RESPONSE", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 272, no. 5258, 5 April 1996 (1996-04-05), pages 50 - 54, XP009039507, ISSN: 0036-8075 *
FRANCISCO J A ET AL: "TRANSPORT AND ANCHORING OF BETA-LACTAMASE TO THE EXTERNAL SURFACE OF ESCHERICHIA COLI", BIOCHEMISTRY, CONSULTANTS BUREAU, NEW YORK, NY, US, vol. 89, 1 April 1992 (1992-04-01), pages 2713 - 2717, XP001203586, ISSN: 0006-2979 *
GEWIRTZ ET AL, THE JOURNAL OF CLINICAL INVESTIGATION, vol. 107, January 2001 (2001-01-01), pages 99 - 109, XP002210842 *
HAYASHI ET AL, NATURE, vol. 410, 26 April 2001 (2001-04-26), pages 1099 - 1103, XP002210843 *
MCEWEN ET AL: "Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagelin leads to partial protection in mice", VACCINE, vol. 10, no. 6, 1992, pages 405 - 411 *
MEDZHITOV R ET AL: "Innate immunity: impact on the adaptive immune response", CURRENT OPINION IN IMMUNOLOGY, CURRENT BIOLOGY LTD, vol. 9, no. 1, February 1997 (1997-02-01), pages 4 - 9, XP004327225, ISSN: 0952-7915 *
NEWTON S M C ET AL: "IMMUNE RESPONSE TO CHOLERA TOXIN EPITOPE INSERTED IN SALMONELLA FLAGELLIN", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 244, no. 4900, 1989, pages 70 - 72, XP001094029, ISSN: 0036-8075 *
RAULY I ET AL: "Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 67, no. 11, November 1999 (1999-11-01), pages 5547 - 5551, XP002138526, ISSN: 0019-9567 *
SCHREUDER M P ET AL: "Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 14, no. 5, April 1996 (1996-04-01), pages 383 - 388, XP004057292, ISSN: 0264-410X *
See also references of WO0209748A1 *
SMITH K D ET AL: "Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility", NATURE IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, vol. 4, no. 12, 1 December 2003 (2003-12-01), pages 1247 - 1253, XP002999619, ISSN: 1529-2908, DOI: 10.1038/NI1011 *
STOCKER ET AL, INTERN. REV. IMMUNOL., vol. 11, 1994, pages 167 - 178, XP000612018 *
UEDA M ET AL: "Genetic immobilization of proteins on the yeast cell surface", BIOTECHNOLOGY ADVANCES, ELSEVIER PUBLISHING, BARKING, GB, vol. 18, no. 2, April 2000 (2000-04-01), pages 121 - 140, XP004205315, ISSN: 0734-9750 *
VAN DE VERG L L ET AL: "Outer membrane protein of Neisseria meningitidis as a mucosal adjuvant for lipopolysaccharide of Brucella melitensis in mouse and guinea pig intranasal immunization models", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, US, vol. 64, no. 12, December 1996 (1996-12-01), pages 5263 - 5268, XP002088714, ISSN: 0019-9567 *
WYANT ET AL, INFECTION AND IMMUNITY, vol. 67, July 1999 (1999-07-01), pages 3619 - 3624, XP002415285 *
WYANT ET AL, INFECTION AND IMMUNITY, vol. 67, March 1999 (1999-03-01), pages 1338 - 1346 *

Also Published As

Publication number Publication date
WO2002009748A9 (en) 2003-04-03
AU2001286405B2 (en) 2007-05-10
CA2418036A1 (en) 2002-02-07
EP1322326A1 (de) 2003-07-02
WO2002009748A1 (en) 2002-02-07
CN1549726A (zh) 2004-11-24
AU8640501A (en) 2002-02-13

Similar Documents

Publication Publication Date Title
EP1322326A4 (de) Gegen das angeborene immunsystem gerichtete impfstoffe
CY2009014I1 (el) Εμβολιο εναντι αντιγονων απο βακτηριδια
EP1307130A4 (de) Impfstoff gegen menschlichen immunschwächevirus
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
ATE312624T1 (de) Impfstoff gegen hpv
DK1228217T3 (da) Konserverede neisseria-antigener
PL363005A1 (pl) Szczepionki
DK1343525T3 (da) Forbedret Mycoplasma hyopneumonia bacterinvaccine
NO20031483D0 (no) Vaksine
NL300311I1 (nl) Adjuvanssytemen en vaccins
NO20034683D0 (no) Intradermal vaksineinnretning
NO20024172L (no) Vaksine
DK1265633T3 (da) Vaccineadjuvans
DE60002650D1 (de) Öladjuvierter Impfstoff
DZ3219A1 (fr) Vaccin
IL189736A0 (en) Vaccine adjuvants
NO20024255D0 (no) HIV-immun adjuvansterapi
FR2715304B1 (fr) Vaccin anti-allergique.
EP1105154A4 (de) Impfstoffe gegen bakterielle superantigene
HUP0401182A3 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
IS6184A (is) Bóluefni gegn ISA veiru
ZA200000142B (en) Adjuvants for use in vaccines.
NO20002213L (no) Babesia vaksine
ITMI992410A0 (it) Vaccino per hiv

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030227

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050629

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20131024

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1055393

Country of ref document: HK